Masimo Co. (NASDAQ:MASI) Stake Boosted by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC grew its stake in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 16,740.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,052 shares of the medical equipment provider's stock after acquiring an additional 5,022 shares during the quarter. Nisa Investment Advisors LLC's holdings in Masimo were worth $835,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. FMR LLC increased its stake in shares of Masimo by 41.2% during the 3rd quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider's stock valued at $900,860,000 after acquiring an additional 1,970,883 shares during the last quarter. State Street Corp increased its position in Masimo by 0.7% during the 3rd quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider's stock worth $191,837,000 after purchasing an additional 10,179 shares in the last quarter. Westfield Capital Management Co. LP increased its position in Masimo by 23.2% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider's stock worth $185,869,000 after purchasing an additional 262,370 shares in the last quarter. Geode Capital Management LLC increased its position in Masimo by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 792,886 shares of the medical equipment provider's stock worth $105,741,000 after purchasing an additional 11,984 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its position in Masimo by 9.8% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 792,166 shares of the medical equipment provider's stock worth $105,619,000 after purchasing an additional 70,440 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a research report on Wednesday, January 22nd. BTIG Research increased their target price on shares of Masimo from $166.00 to $170.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Raymond James increased their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a research report on Friday, December 27th. Stifel Nicolaus reissued a "buy" rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Finally, Wells Fargo & Company increased their price objective on shares of Masimo from $171.00 to $193.00 and gave the company an "overweight" rating in a research report on Wednesday, December 11th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $179.67.

Masimo Stock Up 2.7 %

NASDAQ:MASI traded up $4.64 during trading hours on Tuesday, hitting $175.18. The stock had a trading volume of 624,655 shares, compared to its average volume of 524,956. The company has a market cap of $9.38 billion, a PE ratio of 120.81 and a beta of 1.01. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The business has a 50 day simple moving average of $170.32 and a two-hundred day simple moving average of $142.65. Masimo Co. has a 1-year low of $101.61 and a 1-year high of $180.97.

Masimo (NASDAQ:MASI - Get Free Report) last released its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.84 by $0.14. The company had revenue of $504.60 million during the quarter, compared to analysts' expectations of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The business's revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.63 EPS. Analysts predict that Masimo Co. will post 4.1 EPS for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.